The monarchE committee reported that among patients with early-stage HR+, HER2− breast cancer, and nodal involvement, the addition of abemaciclib to hormone therapy significantly improves cancer-specific free survival and decreases the risk of disease recurrence5–7. The gene discussed is HR; the disease is breast cancer.